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Abstract
Pain is a physiological and adaptive process which occurs to protect organisms from tissue damage and extended
injury. Pain sensation beyond injury, however, is a pathological process which is poorly understood. Experimental
models of neuropathic pain demonstrate that reactive astrocytes contribute to reduced nociceptive thresholds.
Astrocytes release “gliotransmitters” such as D-serine, glutamate, and ATP, which is extracellularly hydrolyzed to
adenosine. Adenosine 1 receptor activation in the spinal cord has anti-nociceptive effects on baseline pain
threshold, but the source of the endogenous ligand (adenosine) in the spinal cord is unknown. In this study we
used a transgenic mouse model in which SNARE-mediated gliotransmission was selectively attenuated (called
dnSNARE mice) to investigate the role of astrocytes in mediating baseline nociception and the development of
neuropathic pain. Under baseline conditions, immunostaining in the dorsal horn of the spinal cord showed
astrocyte-specific transgene expression in dnSNARE mice, and no difference in expression levels of the astrocyte
marker GFAP and the microglia marker Iba1 relative to wild-type mice. The Von Frey filament test was used to
probe sensitivity to baseline mechanical pain thresholds and allodynia following the spared nerve injury model of
neuropathic pain. DnSNARE mice exhibit a reduced nociceptive threshold in response to mechanical stimulation
compared to wild-type mice under baseline conditions, but nociceptive thresholds following spared nerve injury
were similar between dnSNARE and wild-types. This study is the first to provide evidence that gliotransmission
contributes to basal mechanical nociception.
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Findings
Pain sensation is an adaptive response to impending tis-
sue damage that protects an organism from extended
injury. Pain perception involves a series of cellular inter-
actions and responses from immune cells, glia and neu-
rons. Signals from glial cells trigger neuronal responses,
and vice versa, initiating a complex cascade of cell-cell
interactions and feedback mechanisms [1]. A major
obstacle in elucidating the relative contribution of speci-
fic cell types is reflected by the ubiquitous nature of the
signaling molecules that have been implicated in the
behavioral expression of pain. ATP, adenosine and glu-
tamate are not only ubiquitous regulators of normal
nervous system function, being released by and activat-
ing receptors on multiple cell types, these transmitters
are also associated with many neuropathological condi-
tions, including chronic pain.
Acute pain stimuli excite primary nociceptive neurons,
which synapse and release glutamate and substance-P
onto postsynaptic neurons in the dorsal horn of the
spinal cord. Under chronic pain conditions, this synapse
exhibits an LTP-like state where increased responses
from dorsal horn neurons are elicited by afferent stimu-
lation [2]. This is correlated with behavioral outputs
such as reduced threshold to pain (allodynia) and
increased severity of pain sensation (hyperalgesia). The
development of chronic pain is a pathological process
that is not fully understood, however experimental mod-
els of neuropathic pain (NPP) demonstrate that reactive
responses of astrocytes contribute to reduced nocicep-
tive thresholds [3], a hallmark feature of this condition,
but the mechanisms by which this occurs are incomple-
tely defined. Models of NPP also show that microglia
and astrocytes residing in the dorsal horn of the spinal
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characterized by hypertrophic morphology, up-regula-
tion of cell-specific proteins, and proliferation [4]. Astro-
cytes release chemical transmitters, “gliotransmitters”
such as D-serine, glutamate, and ATP [5]. ATP release
by astrocytes or other cell types may influence microglia
[6] or neuronal responses [7] in the spinal cord. In turn,
neuronal release of glutamate and substance P, both of
which increase in pain, may stimulate astrocyte release
of ATP [8]. Recent studies demonstrate that astrocytes
also regulate adenosine 1 receptor (A1R) signaling and
neuronal NMDA receptor (NMDAR) expression and
synaptic plasticity [9]. Given that activation of A1Rs is
anti-nociceptive [10], and since changes in NMDAR
expression and activation contributes to the maladaptive
synaptic plasticity associated with NPP [11], it is possi-
ble astrocytes contribute to the cellular basis of pain
perception. It has been well-established that astrocyte
gliotransmission represents a mechanism for fine-tuning
synaptic activity [12-14], but the impact of this process
as it relates to physiological behaviors, such as pain sen-
sation, are not well-understood. The development of
molecular genetic techniques in which astrocyte func-
tion is selectively impaired has made it possible to probe
the behavioral impact of these glial cells. For example,
using transgenic mice in which SNARE-mediated release
of gliotransmitters is selectively attenuated (called
“dnSNARE” mice), astrocytes were shown to be critical
regulators of A1R-dependent sleep homeostasis [15]. In
this study, dnSNARE mice were used to probe the con-
tribution of gliotransmission to physiological and patho-
logical pain sensation.
DnSNARE mice were created by crossing two lines of
transgenic mice using the tetracycline regulatory system:
in one line of mice, the astrocyte-specific Glial Fibrillary
Acidic Protein (GFAP) promoter was used to drive
expression of tetracycline transactivator, and in the
other line, the tetracycline operator was used to drive
expression of the enhanced green fluorescent protein
(EGFP) reporter gene and dominant-negative expression
of the cytosolic portion of the synaptobrevin complex
(dnSNARE) to attenuate vesicle fusion [12]. This system
allows for inducible transgene expression through
removal of doxycycline from the diet. Previous studies
show astrocyte-selective transgene expression through-
out the brain, including the cortex, hippocampus, and
basal forebrain [12,15]. To confirm astrocyte-specific
transgene expression in the spinal cord, levels L4 to L6
were histologically examined. Immunostaining against
GFAP shows colocalization with the EGFP transgene,
whereas the microglial marker Iba1 and the neuronal
marker NeuN do not (n = 3; EGFP+/GFAP+ cells =
69.2 ± 7.3%; EGFP+/NeuN+ and EGFP+/Iba1+ cells = 0;
P < 0.001) suggesting that dnSNARE is expressed
selectively in astrocytes (Figure 1A, B). Reactive
responses in astrocytes and microglia, quantified as per-
cent area of substantia gelatinosa above background
staining of GFAP (WT: 22.7 ± 2.4% n = 3; dnSNARE:
20.6 ± 1.2% n = 3; P = 0.24) and Iba1 (WT: 10.7 ± 0.5%
n = 3; dnSNARE: 10.3 ± 0.2% n = 3; P = 0.20), are simi-
lar in the spinal cords of dnSNARE and WT mice (Fig-
ure 1C).
S i n c ea s t r o c y t i ce x p r e ssion of dnSNARE causes
reduced A1R activation [15], and stimulation of this
receptor in the spinal cord has anti-nociceptive effects
on baseline pain [10], we hypothesized that dnSNARE
mice would have altered basal nociception. We mea-
sured mechanical nociception in WT and dnSNARE
adult male mice, aged 8-10 weeks, using von Frey fila-
ments, a method in which a constant pressure is applied
to the plantar surface of the hind paw and subsequent
paw withdrawal threshold is measured. DnSNARE mice
exhibit a reduced threshold to mechanical nociception
(WT: 1.24 ± 0.13 n = 18; dnSNARE: 0.86 ± 0.08 n = 21;
p < 0.01), suggesting they have increased baseline sensi-
tivity to pain (Figure 1D). Given that acute pain sensa-
tion is a spinal reflex, we anticipate that this effect is
mediated by dorsal horn astrocytes. However, we cannot
rule out the potential contribution of supraspinal brain
regions, such as the rostral ventral medulla or anterior
cingulate cortex, where dnSNARE expressing astrocytes
are also present (not shown). Furthermore, it is unlikely
that satellite glial cells in the dorsal root ganglion are
involved as GFAP is not highly expressed in these cells
before injury [16].
Given that baseline nociception is altered in dnSNARE
mice, and since these mice are known to exhibit
reduced release of ATP, a purine known to play impor-
tant roles in neuropathic pain, we asked whether astro-
cytic dnSNARE expression alters the development of
N P P .T h es p a r e dn e r v ei n j u r y( S N I )m e t h o do fN P P
[17-19] was used to test this hypothesis. One day follow-
ing measurement of baseline nociception, mice were
anesthetized and the tibial and peroneal branches of the
sciatic nerve were ligated, sparing the sural branch. Ani-
mals were allowed to recover from surgery and Von
Frey monofilaments were used to test NPP at 3, 7, 10,
14, 21, and 28 days post-injury (dpi). Despite a clear dif-
ference in basal pain perception, dnSNARE mice exhibit
progressive development of NPP after SNI, similar to
WT mice (FIG 1D; WT: n = 9 for 3-21 dpi, n = 7 for
28 dpi; dnSNARE: n = 12 for 3-21 dpi, n = 7 for 28 dpi;
P = 0.570).
This study shows that gliotransmission modulates
physiological mechanical nociception. Given that admin-
istration of A1R agonists are known to decrease pain
responses [10] and that previous studies show dnSNARE
mice exhibit reduced adenosine tone [15], we speculate
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Figure 1 Astrocyte Specific Attenuation of Gliotransmission Causes Reduced Basal Nociception but Does Not Alter NPP. (A) The lumbar
spinal cord exhibits abundant expression of EGFP reporter protein (green) with distinct colocalization with the astrocyte marker, GFAP (red; left),
but not with the neuronal marker NeuN (red; right). (B) Quantification of EGFP+ cells reveals that 69.2 ± 7.3% GFAP+ cells were EGFP+ in
dnSNARE mice but 0% colocalization was present Iba1+ or NeuN+ cells. No EGFP+ cells were found in WT sections (not shown). (C) dnSNARE
expression does not cause reactive astrocytes or microglia as shown by similar GFAP (WT: 22.7 ± 2.4% n = 3; dnSNARE: 20.6 ± 1.2% n = 3; P =
0.24) and Iba1 (WT: 10.7 ± 0.5% n = 3; dnSNARE: 10.3 ± 0.2% n = 3; P = 0.20) staining between dnSNARE and WT dorsal horns. (D) DnSNARE
mice exhibit a significant reduction in baseline paw withdrawal thresholds compared to WT mice (WT: 1.24 ± 0.13 n = 18, dnSNARE: 0.86 ± 0.08
n = 21 *P < 0.01). (E) DnSNARE and WT mice both exhibit sustained reduction in paw withdrawal threshold after SNI with no significant
difference between WT and dnSNARE (WT: n = 9 for 3-21 dpi, n = 7 for 28 dpi dnSNARE: n = 12 for 3-21 dpi, n = 7 for 28 dpi P = 0.570). Scale
bars: 10 μm (upper); 100 μm (lower). dpi, days post injury.
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dnSNARE mice is due to decreased A1R activation in
the spinal cord. This would suggest that an astrocytic
source of adenosine contributes to acute pain signaling
in the spinal cord. However, we cannot discount the
possibility of additional contributions from other glio-
transmitters such as D-serine [20].
Astrocytes have been recently promoted from being
merely the “glue” that supports neurons, to key players
in synaptic activity and homeostatic regulators of ner-
vous system function. We now know they are integrally
involved in neuronal activity and are starting to learn
more about how astrocyte function impacts behavior.
Our results showing that a mouse model of attenuated
gliotransmission exhibits a reduction in baseline
mechanical nociception is the first indication that astro-
cytes modulate physiological pain behavior.
Methods
dnSNARE mouse
The tTA tet-O system was used to create inducible
astrocyte-specific expression of dnSNARE, a dominant
negative mutation of the synaptobrevin II protein in the
SNARE complex. Two mouse lines were crossed to
achieve inducible expression of dnSNARE selectively in
astrocytes, the tetracycline transactivator line was driven
by the astrocyte specific GFAP promoter, and the
dnSNARE, GFP and Lac-Z reporter genes were driven
by the tetracycline operator [12,15,21]. Mice were raised
on doxycycline to prevent transgene expression during
development and thus to prevent potential adaptations
to transgene expression. Doxycycline was removed from
the diet at weaning to permit transgene expression in
the mature animal. Two weeks post doxycycline
removal, abundant transgene expression was evident
throughout the brain and spinal cord. Male animals
were tested at 8-10 weeks of age and were housed on a
12 hr/12 hr light/dark cycle. All procedures were in
strict accordance with National Institutes of Health
Guide for Care and Use of Laboratory Animals and
were approved by the Tufts University Institutional Ani-
mal Care and Use Committee.
Behavioral Testing
Von Frey monofilaments were used to test baseline
mechanical nociception as well as allodynia after SNI.
The monofilaments were used to apply controlled force
to the lateral portion of the left hind limb, similar to
what has been previously described [17-19]. Animals
were tested in wire mesh chambers to which they were
habituated 5 days before testing. Pain threshold was
recorded when animals elicited 4-5/10 pain responses
(defined by rapid paw withdrawals often with paw shak-
ing or licking) for a given monofilament ranging from
0.02 g to 2 g. A subset of animals was tested for NPP
after SNI. Surgery was performed under isoflurane
anesthesia and the tibial and peroneal branches of the
sciatic nerve were ligated while the sural branch was
spared [17]. Beginning 3 dpi, changes in mechanical
nociceptive responses were measured using von Frey’s
fiber test. Measurements were taken as described above,
and trials were repeated on 3, 7, 10, 14, 21, and 28 dpi.
Criteria for exclusion identified outliers (> 2 standard
deviations from within group mean), which were
excluded from this study (2 dnSNARE, 1 WT). Upon
completion of the experiments the animals were eutha-
n i z e db yi s o f l u r a n ef o l l o w e db yc a r d i a cp e r f u s i o n ,f o r
histology.
Immunohistochemistry
Mice (3 wild-type and 3 dnSNARE) were transcardially
perfused with 4% paraformaldehyde in phosphate buf-
f e r e ds a l i n e( P B S )a n dp o s t - f i x e df o r2 4h o u r s .S p i n a l
cords were removed from spinal column and placed in
10% and then 30% sucrose. The lumbar spinal cord
(L4-L6) was sectioned on a sliding microtome at a
thickness of 40 μm and placed in PBS. Sections were
stained with Rabbit anti-Iba-1 (Wako, 1:1000) chicken
anti-GFAP (abcam, 1:1000), and mouse anti-Neu-N
(chemicon, 1:1000). Secondary antibodies conjugated to
Alexafluor were used. Goat anti-rabbit Alexa633, goat
anti-chicken Alexa546 and goat anti-mouse Alexa633
were used, all at a 1:500 dilution. At least three repre-
sentative sections were taken from each condition for
quantification.
Confocal imaging
Confocal images were acquired using a Nikon Eclipse Ti
microscope. The substantia gelatinosa of the dorsal horn
was imaged. For imaging of reactive changes in astro-
cytes and microglia, maximum intensity projections
were created from 10 μm Z-stacks taken with a 20×
objective (0.75 NA). ImageJ software was used to mea-
sure the percent area above threshold for each antibody.
Background values were subtracted. For counting of co-
localization, single plane optical section images (60×
objective, 1.40 NA) were taken and each clearly defined
cell was counted as EGFP positive or negative based on
localization of astrocyte, microglia or neuron markers
with DAPI labeled nuclei.
Statistics
Student’s t-test was used to determine significance
between baseline pain groups and IHC quantification.
Repeated Measures 2-Way ANOVA was used to deter-
mine whether a difference existed in NPP development
between genotypes. Raw data were transformed to
Log10 for ANOVA analysis.
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NPP: neuropathic pain; A1R: adenosine 1 receptor; SNI: spared nerve injury;
GFAP: glial fibrillary acidic protein; dpi: days post injury; EGFP: enhanced
green fluorescent protein; NMDAR: N-methyl D-aspartate Receptor.
Acknowledgements
The authors would like to thank Clifford J. Woolf, MB, BCh, PhD and Joachim
Scholz, MD for their intellectual contributions to this project. This work was
funded by NIH/NINDS (NS037585), NIH/NIAAA (AA019902), and NIH/NIDA
(DA025967).
Authors’ contributions
JF and SM contributed equally to the manuscript. JF, SM, and PH designed
the experiments. Experiments and data analysis were carried out by JF and
SM. JF, SM drafted the manuscript. All authors read and approved the final
manuscript.
Competing interests
PH has equity interest in Gliacure Inc.
Received: 19 October 2011 Accepted: 2 December 2011
Published: 2 December 2011
References
1. Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cells
and glia. Nat Neurosci 2007, 10:1361-1368.
2. Liu X, Sandkühler J: Characterization of long-term potentiation of C-fiber-
evoked potentials in spinal dorsal horn of adult rat: essential role of NK1
and NK2 receptors. J Neurophysiol 1997, 78:1973-1982.
3. Ren K, Dubner R: Neuron-glia crosstalk gets serious: role in pain
hypersensitivity. Curr Opin Anaesthesiol 2008, 21:570-579.
4. Romero-Sandoval A, Chai N, Nutile-McMenemy N, Deleo JA: A comparison
of spinal Iba1 and GFAP expression in rodent models of acute and
chronic pain. Brain Res 2008, 1219:116-126.
5. Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG: Glutamate-
mediated astrocyte-neuron signaling. Nature 1994, 30:744-747.
6. Inoue K, Tsuda M, Koizumi S: ATP receptors in pain sensation:
Involvement of spinal microglia and P2X(4) receptors. Purinergic Signal
2005, 1:95-100.
7. Nakatsuka T, Gu JG: ATP P2X receptor-mediated enhancement of
glutamate release and evoked EPSCs in dorsal horn neurons of the rat
spinal cord. J Neurosci 2001, 21:6522-6531.
8. Werry EL, Liu GJ, Bennett MR: Glutamate-stimulated ATP release from
spinal cord astrocytes is potentiated by substance P. J Neurochem 2006,
99:924-936.
9. Deng Q, Terunuma M, Fellin T, Moss SJ, Haydon PG: Astrocytic activation
of A1 receptors regulates the surface expression of NMDA receptors
through a Src kinase dependent pathway. Glia 2011, 59:1084-1093.
10. Gong QJ, Li YY, Xin WJ, Wei XH, Cui Y, Wang J, Liu Y, Liu CC, Li YY, Liu XG:
Differential effects of adenosine A1 receptor on pain-related behavior in
normal and nerve-injured rats. Brain Res 2010, 1361:23-30.
11. Bleakman D, Alt A, Nisenbaum ES: Glutamate receptors and pain. Semin
Cell Dev Biol 2006, 17:592-604.
12. Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY,
Takano H, Moss SJ, McCarthy K, Haydon PG: Astrocytic purinergic signaling
coordinates synaptic networks. Science 2005, 310:113-116.
13. Panatier A, Vallée J, Haber M, Murai KK, Lacaille J, Robitaillesend R:
Astrocytes are endogenous regulators of basal transmission at central
synapses. Cell 2011, 146:785-798.
14. Volterra A, Meldolesi J: Astrocytes, from brain glue to communication
elements: the revolution continues. Nat Rev Neurosci 2005, 6:626-640.
15. Halassa MM, Florian C, Fellin T, Munoz JR, Lee SY, Abel T, Haydon PG,
Frank MG: Astrocytic modulation of sleep homeostasis and cognitive
consequences of sleep loss. Neuron 2009, 61:213-219.
16. Ohara PT, Vit JP, Bhargava A, Romero M, Sundberg C, Charles AC, Jasmin L:
Gliopathic pain: when satellite glial cells go bad. Neuroscientist 2009,
15:450-63.
17. Bourquin AF, Süveges M, Pertin M, Gilliard N, Sardy S, Davison AC,
Spahn DR, Decosterd I: Assessment and analysis of mechanical allodynia-
like behavior induced by spared nerve injury (SNI) in the mouse. Pain
2006, 122:14.e1-14.e14.
18. Decosterd I, Woolf CJ: Spared nerve injury: an animal model of persistent
peripheral neuropathic pain. Pain 2000, 87:149-158.
19. Scholz J, Abele A, Marian C, Häussler A, Herbert TA, Woolf CJ, Tegeder I:
Low-dose methotrexate reduces peripheral nerve injury-evoked spinal
microglial activation and neuropathic pain behavior in rats. Pain 2008,
138:130-142.
20. Miraucourt LS, Peirs C, Dallel R, Voisin DL: Glycine inhibitory dysfunction
turns touch into pain through astrocyte-derived D-serine. Pain 2011,
152:1340-8.
21. Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G:
Neuronal synchrony mediated by astrocytic glutamate through
activation of extrasynaptic NMDA receptors. Neuron 2004, 43:729-743.
doi:10.1186/1744-8069-7-93
Cite this article as: Foley et al.: Gliotransmission modulates baseline
mechanical nociception. Molecular Pain 2011 7:93.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Foley et al. Molecular Pain 2011, 7:93
http://www.molecularpain.com/content/7/1/93
Page 5 of 5